株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

類鼻疽- パイプライン製品の分析

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321927
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
類鼻疽- パイプライン製品の分析 Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2016
出版日: 2016年11月30日 ページ情報: 英文 56 Pages
概要

類鼻疽は、グラム陰性の好気性双極桿菌で土壌中に生息するバクテリアによっておこる感染症です。このバクテリアは吸入、摂取、傷口などから動物およびヒト双方に感染し、症状は発熱、咳、胸痛、頭痛、食欲不振などがあります。

当レポートでは、類鼻疽に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

類鼻疽の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • Bavarian Nordic A/S 14
  • Emergent BioSolutions Inc. 15
  • Evolva SA 16
  • Soligenix, Inc. 17
  • Syntiron LLC 18

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • Burkholderia pseudomallei vaccine
  • burkholderia vaccine
  • EV-035
  • GC-072
  • SGX-101
  • SGX-942
  • SGX-943
  • Small Molecules to Inhibit FtsZ Protein for Bacterial Infections
  • Small Molecules to Inhibit InhA for Infectious Diseases

最新のパイプライン製品情報

開発休止中のプロジェクト

製品開発のマイルストーン

  • 注目のニュースおよびプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8756IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2016, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.

Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Burkholderia pseudomallei Infections (Melioidosis).

Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Burkholderia pseudomallei Infections (Melioidosis) Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Overview 7
  • Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis 8
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Development by Companies 9
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Investigation by Universities/Institutes 10
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Products Glance 11
  • Early Stage Products 11
  • Burkholderia pseudomallei Infections (Melioidosis) - Products under Development by Companies 12
  • Burkholderia pseudomallei Infections (Melioidosis) - Products under Investigation by Universities/Institutes 13
  • Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development 14
  • Bavarian Nordic A/S 14
  • Emergent BioSolutions Inc 15
  • Grifols SA 16
  • Soligenix Inc 17
  • Syntiron LLC 18
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment 19
  • Assessment by Monotherapy Products 19
  • Assessment by Target 20
  • Assessment by Mechanism of Action 22
  • Assessment by Route of Administration 24
  • Assessment by Molecule Type 26
  • Drug Profiles 28
  • ARD-3100 - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • ARD-3150 - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • Burkholderia pseudomallei vaccine - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • Burkholderia vaccine - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • dusquetide - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • EV-035 - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • GC-072 - Drug Profile 46
  • Product Description 46
  • Mechanism Of Action 46
  • R&D Progress 46
  • melioidosis vaccine - Drug Profile 47
  • Product Description 47
  • Mechanism Of Action 47
  • R&D Progress 47
  • SGX-943 - Drug Profile 48
  • Product Description 48
  • Mechanism Of Action 48
  • R&D Progress 48
  • Small Molecules for Infectious Diseases - Drug Profile 49
  • Product Description 49
  • Mechanism Of Action 49
  • R&D Progress 49
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects 50
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products 51
  • Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones 52
  • Featured News & Press Releases 52
  • May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis 52
  • Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 52
  • Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072 53
  • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 53
  • Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 53
  • Appendix 55
  • Methodology 55
  • Coverage 55
  • Secondary Research 55
  • Primary Research 55
  • Expert Panel Validation 55
  • Contact Us 55
  • Disclaimer 56

List of Tables

  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2016 7
  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Number of Products under Investigation by Universities/Institutes, H2 2016 10
  • Comparative Analysis by Early Stage Development, H2 2016 11
  • Products under Development by Companies, H2 2016 12
  • Products under Investigation by Universities/Institutes, H2 2016 13
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H2 2016 14
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc, H2 2016 15
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols SA, H2 2016 16
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H2 2016 17
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H2 2016 18
  • Assessment by Monotherapy Products, H2 2016 19
  • Number of Products by Stage and Target, H2 2016 21
  • Number of Products by Stage and Mechanism of Action, H2 2016 23
  • Number of Products by Stage and Route of Administration, H2 2016 25
  • Number of Products by Stage and Molecule Type, H2 2016 27
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2016 50
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2016 51

List of Figures

  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H2 2016 8
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Number of Products by Targets, H2 2016 20
  • Number of Products by Stage and Targets, H2 2016 20
  • Number of Products by Mechanism of Actions, H2 2016 22
  • Number of Products by Stage and Mechanism of Actions, H2 2016 22
  • Number of Products by Routes of Administration, H2 2016 24
  • Number of Products by Stage and Routes of Administration, H2 2016 24
  • Number of Products by Molecule Types, H2 2016 26
  • Number of Products by Stage and Molecule Type, H2 2016 26
Back to Top